The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients - Trial NCT06357806
Access comprehensive clinical trial information for NCT06357806 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing 302 Hospital and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing 302 Hospital
Timeline & Enrollment
N/A
May 01, 2024
Oct 30, 2025
Primary Outcome
The rate of HBsAg loss at 24 weeks and 48 weeks.,Incidence of treatment-emergent adverse events/serious adverse events
Summary
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety
 of treatment with Sintilimab (PDL-1 antibody) combined Peg-IFNα-2b in CHB patients on stable
 NAs treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06357806
Non-Device Trial